A Study of Modified Release RTN-001 In Patients With Uncontrolled Hypertension

A phase 2 trial registered on ClinicalTrials.gov. The registry status is recruiting. It plans to enroll 280 participants.

Also called NCT07142356

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; triple masking; primary purpose treatment
Phase
Phase 2
Enrolled
  • 280 participants (planned count) (from the registry)
Sponsor
Retension Pharmaceuticals. Inc. (from the registry)
Registry
  • NCT NCT07142356
Started
(actual) (from the registry)
Primary completion
(anticipated) (from the registry)
Completion
(anticipated) (from the registry)
Countries
United States (from the registry)
Registry status
  • Recruiting (from the registry)

Technical summary

Registry record NCT07142356. Randomized; triple masking; primary purpose treatment. Start 2025-10-31 (actual); primary completion 2027-03 (anticipated). Results not posted.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
A Study of Modified Release RTN-001 In Patients With Uncontrolled Hypertension
Condition
Uncontrolled Hypertension
Intervention (Drug)
RTN-001
Intervention (Drug)
Matching placebo control
Lead sponsor
Retension Pharmaceuticals. Inc. (class: industry)

Record details

Record id
cardio:ct-nct07142356
Content hash
ab08a367a35be4a10bdd3eb1d20ad66a28311586f1250992d63860380f2dbf30